spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  pegylation 

 HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Feb 2014
Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Dec 2012
Savient Announces the Election of Robert G. Savage to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2012
Savient Receives Positive CHMP Opinion for KRYSTEXXA(R) Approval in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2012
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2012
Savient Announces Named Patient Programme for KRYSTEXXA(R) in the European Union for Patients with Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2012
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 3 Nov 2011
Savient Pharmaceuticals Receives J-code for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 6 Sep 2011
Savient Announces the Election of William F. Owen, Jr., M.D. and David Y. Norton to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2011
Savient Pharmaceuticals Names Rheumatology Veteran Kenneth M. Bahrt, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2011
Sangart Announces Closing of $50 Million Series G Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Feb 2011
Savient Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2011
Geron Appoints David Greenwood President, Interim CEO and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2011
Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2011
Savient Pharmaceuticals Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2010
Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Feb 2010
Enzon Board of Directors Appoints Executive Committee
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2010
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Dec 2009
Dennis Winger Joins Nektar Therapeutics' Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2009
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2009
Versartis, Inc. Completes Series A Funding of $11 Million [EUR 7.9 M] in a Joint Venture Between Index Ventures and Amunix, Inc.
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Mar 2009
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Enzon Announces IND Acceptance for Its Survivin Antagonist
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Feb 2009
Enzon Discontinues Further Development of rhMBL
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2008
Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Aug 2008
Enzon Pharmaceuticals Announces Intention to Explore Strategic Alternatives for Specialty Pharmaceuticals Business
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2008
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2008
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2008
Enzon Pharmaceuticals, Inc. Announces Plan to Spin-off Biotechnology Business
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 9 Apr 2008
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Biopharmaceuticals Endocrinology Oncology
 HSMN NewsFeed - 14 Feb 2008
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2008
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2008
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2007
Nektar Promotes John Nicholson to Serve as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2007
Pfizer and Nektar Reach Agreement on Exubera(R)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 18 Oct 2007
Nektar Therapeutics Issues Statement on Exubera
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Aug 2007
Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2007
Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 2 Jun 2007
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2007
Nektar Announces New Organizational Structure and Spending Reduction Initiatives to Solidify the Company's Leadership Position in PEGylation and Pulmonary Drug Development
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
Enzon Receives FDA Clearance of Its Recently Filed PEG-SN38 IND Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Apr 2007
FDA Grants Full Approval for DepoCyt(R) for the Treatment of Lymphomatous Meningitis
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 9 Apr 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2006
Celsion Obtains from Valentis Exclusive Rights to Pegylation Patents for use with Heat Activated Liposomes
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Jul 2006
Nektar and University of Alabama in Huntsville Announce Agreement to Settle Litigation
Biopharmaceuticals Drug Delivery Litigation
Return to NewsFeed  

 Additional items found! 38

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 38 additional stories matching:
pegylation
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!